首页> European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)> Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma

导出原文传递

翻译打印收藏纠错

第一作者： Wong S.K.

作者： Wong S.K. ^[1] ; Blum S.M. ^[2] ; Sun X. ^[3] ; Da Silva I.P. ^[4] ; Zubiri L. ^[5] ; Ye F. ^[6] ; Bai K. ^[7] ; Zhang K. ^[8] ; Ugurel S. ^[9] ; Zimmer L. ^[10] ; Livingstone E. ^[11] ; Schadendorf D. ^[12] ; Serra-Bellver P. ^[13] ; Munoz-Couselo E. ^[14] ; Ortiz C. ; Lostes J. ; Huertas R.M. ; Arance A. ; Pickering L. ; Long G.V. ; Carlino M.S. ; Buchbinder E.I. ; Vazquez-Cortes L. ; Jara-Casas D. ; Marquez-Rodas I. ; Gonzalez-Espinoza I.R. ; Balko J.M. ; Menzies A.M. ; Sullivan R.J. ; Johnson D.B.

作者单位： Department of Medicine Vanderbilt University Medical Center ^[1] University of Sydney Melanoma Institute Australia ^[2] Department of Medicine Massachusetts General Hospital ^[3] The Christie NHS Foundation Trust ^[4] University Hospital Vall D'Hebron Vall D'Hebron Institute of Oncology ^[5] Hospital Clinic de Barcelona ^[6] Department of Biostatistics Vanderbilt University Medical Center ^[7] University Hospital Essen University of Duisburg-Essen ^[8] The Royal Marsden NHS Foundation Trust ^[9] Department of Medical Oncology Dana-Farber Cancer Institute ^[10] Clínica Médica ARCOS ^[11] University Hospital October 12 ^[12] Hospital ángeles Puebla ^[13] Hospital General Universitario Gregorio Mara?on ^[14]

关键词 Age CTLA-4 Hepatitis Immune checkpoint inhibitor Melanoma PD-1 Young

发布时间 2023-04-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交